舍雷肽酶肠溶片联合噻托溴铵治疗支气管扩张症的疗效观察

Clinical observation of Serrapeptase Enteric-coated Tablets combined with tiotropium bromide in treatment of bronchiectasis

目的探讨舍雷肽酶肠溶片联合噻托溴铵粉吸入剂治疗支气管扩张症的临床疗效。方法对2015年9月—2016年9月在延安大学附属医院接受治疗的86例支气管扩张症患者临床资料进行回顾性分析,根据治疗方案的差别分为治疗组和对照组,每组各43例。对照组用吸入器吸入噻托溴铵粉吸入剂,18μg/次,1次/d。治疗组在对照组基础上口服舍雷肽酶肠溶片,1片/次,3次/d。两组患者均连续治疗7 d。观察两组的临床疗效,比较两组治疗前后咳嗽程度评分、咳痰量评分、肺部啰音评分、第一秒用力呼气容积(FEV1)、用力肺活量(FVC)、最大呼气流速(PEF)的变化情况。结果治疗后,对照组和治疗组的总有效率分别为81.40%、97.67%,两组比较差异有统计学意义(P<0.05)。治疗后,两组患者咳嗽程度评分、咳痰量评分、肺部啰音评分均显著降低,FEV1、FVC、PEF均显著升高,同组治疗前后比较差异有统计学意义(P<0.05);治疗后治疗组咳嗽程度评分、咳痰量评分、肺部啰音评分低于对照组,FEV1、FVC、PEF高于对照组,两组比较差异具有统计学意义(P<0.05)。结论舍雷肽酶肠溶片联合噻托溴铵粉吸入剂治疗支气管扩张症具有较好的临床疗效,可明显改善患者的临床症状和肺功能,具有一定的临床推广应用价值。

Objective To evaluate the clinical efficacy of Serrapeptase Enteric-coated Tablets combined with tiotropium bromide in treatment of bronchiectasis. Methods The clinical data of 86 patients with bronchiectasis who were treated in Yan＇an University Affiliated Hospital from September 2015 to September 2016 were retrospectively analyzed. They were divided into the control and treatment groups based on different treatment, and each group had 43 cases. The patients in the control group were inhalated Tiotropium Bromide Powder for inhalation with inhaler suction, 18 μg/time, once daily. The patients in the treatment group were po administered with Serrapeptase Enteric-coated Tablets on the basis of the control group, 1 tablet/time, three times daily. The patients in two groups were treated for 7 d. After treatment, the efficacy was evaluated, and the changes of cough degree score, sputum volume score, lung rale score, FEV1, FVC, and PEF in two groups before and after treatment were compared. Results After treatment, the efficacies in the control and treatment groups were 81.40% and 97.67%, respectively, and there were differences between two groups （P 〈 0.05）. After treatment, cough degree score, sputum volume score, and lung rale score in the two groups were significantly decreased, and FEV1, FVC, and PEF were significantly increased, and the difference was statistically significant in the same group （P 〈 0.05）. After treatment, cough degree score, sputum volume score, and lung rale score in the treatment group were lower than those in the control group, and FEV1, FVC, and PEF in the treatment group were higher than those in the control group, with significant difference between two groups （P 〈 0.05）. Conclusion Serrapeptase Enteric-coated Tablets combined with tiotropium bromide has clinical curative effect in treatment of bronchiectasis, and can obviously improve the clinical symptoms and lung fimction, which has a certain clinical application value.